Merrill reiterates Actelion at neutral

Actelion was reiterated at neutral by Merrill Lynch analyst Erica Whittaker on the belief that a continued rise in new patients presenting with pulmonary hypertension will fuel strong sales of Tracleer through the middle of 2007. Merrill revised its 2006 operating profit forecast to CHF 26.5 million from CHF 230 million. While Tracleer continues to beat expectations, there is concern that sales growth, in the longer term, will be at risk from competition by Myogen/Gilead's ambrisentan entering the market possibly in mid-2007. Shares of the Allschwil, Switzerland-based pharmaceutical company were up CHF 2.50, or 1.28%, at CHF 198.00. (Swiss: ATLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.